Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Ankit Bharat, MD, can still remember Cornelia Tischmacher stopping their first telehealth conversation every few words to ...

A 56-year-old man presented for 3 weeks of intermittent blurred vision and photophobia.His medical history included type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

Non-Small Cell Lung Cancer says. The clinical trial, which was announced as a breakthrough in 2022, is described as an “innovative alternative treatment for select patients,” by Northwestern ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

Peluntamig targets DLL3 and CD47, potentially enhancing immune recognition and attack on cancer cells. The SKYBRIDGE study is a phase 1/2 trial assessing peluntamig's safety and efficacy in ...

Additionally, researchers found a precursor cell for one of the most common forms of lung cancer; the James Webb Space Telescope detected the faintest, oldest galaxy groups yet; and researchers ...

Background: The combination of amivantamab and lazertinib has demonstrated clinically significant and sustained antitumor effects in both treatment-naïve and osimertinib-pretreated advanced non-small ...

1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...